Chemoradiation with novel agents for rectal cancer.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical colorectal cancer

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CCC.2002.N.008PMID 12453333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

  2001cited by this paper
• Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

  2001cited by this paper
• Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse.

  2001cited by this paper
• DUTCH COLORECTAL CANCER GROUP. PREOPERATIVE RADIOTHERAPY COMBINED WITH TOTAL MESORECTAL EXCISION FOR RESECTABLE RECTAL CANCER

  2001cited by this paper
• NF-kappa B signaling pathway as a target for human tumor radiosensitization.

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin.

  2001cited by this paper
• NF-κB signaling pathway as a target for human tumor radiosensitization

  2001cited by this paper
• Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial.

  2001cited by this paper
• A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

  2001cited by this paper
• Adjuvant radiation therapy of rectal cancer.

  2001cited by this paper
• Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

  2000cited by this paper
• Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin

  2000cited by this paper
• In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

  2000cited by this paper
• Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).

  2000cited by this paper
• Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition.

  2000cited by this paper
• Preoperative radiotherapy for resectable rectal cancer: A meta-analysis.

  2000cited by this paper
• Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.

  1999cited by this paper
• Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future

  1999cited by this paper
• Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation

  1999cited by this paper
• Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.

  1999cited by this paper
• NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B.

  1999cited by this paper
• Enhancement of Tumor Response to γ-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme

  1999cited by this paper
• Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer

  1998cited by this paper
• The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis.

  1998cited by this paper
• Ongoing and unsaid on oxaliplatin: the hope.

  1998cited by this paper
• SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids.

  1997cited by this paper
• Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

  1997cited by this paper
• Improved survival with preoperative radiotherapy in resectable rectal cancer.

  1997cited by this paper
• Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.

  1997cited by this paper
• Epidermal growth factor receptor family and chemosensitization.

  1997cited by this paper
• Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine).

  1997cited by this paper
• Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

  1997cited by this paper
• Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.

  1997cited by this paper
• Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells.

  1996cited by this paper
• Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.

  1996cited by this paper
• Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts

  1996cited by this paper
• Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)

  1996cited by this paper
• Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).

  1996cited by this paper
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

  1996cited by this paper
• Irradiation-enhanced binding of carboplatin to DNA.

  1995cited by this paper
• Preclinical characteristics of gemcitabine

  1995cited by this paper
• Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

  1995cited by this paper
• Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

  1995cited by this paper
• Irradiation enhances cellular uptake of carboplatin.

  1995cited by this paper
• Induction of apoptosis by gemcitabine.

  1995cited by this paper
• Radiosensitization of human tumor cells by gemcitabine in vitro.

  1995cited by this paper
• Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.

  1995cited by this paper
• Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.

  1994cited by this paper
• Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

  1994cited by this paper
• Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.

  1994cited by this paper
• Chemotherapy for colorectal cancer.

  1994cited by this paper
• Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells.

  1994cited by this paper
• Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.

  1994cited by this paper
• The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities.

  1994cited by this paper
• Postoperative radiation therapy for high-risk colon carcinoma.

  1993cited by this paper
• In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

  1993cited by this paper
• Phase II study of gemcitabine in advanced colorectal adenocarcinoma

  1992cited by this paper
• Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro.

  1992cited by this paper
• Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I.

  1992cited by this paper
• Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

  1991cited by this paper
• Effective surgical adjuvant therapy for high-risk rectal carcinoma.

  1991cited by this paper
• Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

  1989cited by this paper
• Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience.

  1988cited by this paper
• Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

  1988cited by this paper
• Increase in radioresponse of murine tumors by treatment with indomethacin.

  1988cited by this paper
• Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

  1988cited by this paper
• Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

  1987cited by this paper
• Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells.

  1986cited by this paper
• Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

  1986cited by this paper
• Carboplatin as a potentiator of radiation therapy.

  1985cited by this paper
• Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

  1985cited by this paper
• Toxic variability and radiation sensitization by Pt(II) analogs in Salmonella typhimurium cells.

  1984cited by this paper
• Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

  1983cited by this paper
• Mutagenicity, cytotoxicity, and DNA binding of platinum(II)-chloroammines in Chinese hamster ovary cells.

  1980cited by this paper
• Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

  1966cited by this paper

• The treatment model of stage II/III rectal cancer: A study based on the SEER database.

  2023cites this paper
• A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer

  2022cites this paper
• Chondroitin sulfate modification enhances the targeting and therapeutic effect of nanomedicine on AOM/DSS-induced mouse colon cancer

  2019cites this paper
• Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer.

  2016cites this paper
• Genetic polymorphisms in 5-FU related enzymes predict pathologic response following neoadjuvant chemoradiation for rectal cancer

  2016cites this paper
• Identification of genetic markers that predict cancer sensitivity to the anticancer drugs 5-FU and Irinotecan

  2015cites this paper
• A Prospective Study of Preoperative Oxaliplatin and 5-fluorouracil with Concurrent Radiotherapy in Patients with Locally Advanced Rectal Cancer

  2014cites this paper
• New directions in neoadjuvant therapy for rectal cancer

  2011cites this paper
• Concurrent Chemotherapy-Enhanced Radiation: Trials and Conclusions

  2010cites this paper
• Experimental Radiosensitization and Molecular Prediction of Chemoradiotherapy Response in Rectal Cancer

  2009cites this paper
• Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial

  2008cites this paper
• Radiotherapy for localized rectal cancer.

  2007cites this paper
• Phase II study of neoadjuvant concurrent chemioradiotherapy with oxaliplatin-containing regimen in locally advanced rectal cancer.

  2006cites this paper
• Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation

  2006cites this paper
• Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results.

  2005cites this paper
• Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.

  2004cites this paper
• 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation.

  2004cites this paper
• Neoadjuvant treatment for locally advanced rectal carcinoma.

  2004cites this paper
• Histone deacetylase inhibitors FK228, N‐(2‐aminophenyl)‐4‐[N‐(pyridin‐3‐yl‐methoxycarbonyl)amino‐ methyl]benzamide and m‐carboxycinnamic acid bis‐hydroxamide augment radiation‐induced cell death in gastrointestinal adenocarcinoma cells

  2004cites this paper
• Radiotherapy and Oral Capecitabine in the Preoperative Treatment of Patients with Rectal Cancer: Rationale, Preliminary Results and Perspectives

  2003cites this paper
• The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines

  2003cites this paper